Alaunos Therapeutics (TCRT) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $3.7 million.
- Alaunos Therapeutics' Liabilities and Shareholders Equity rose 490.14% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 million, marking a year-over-year decrease of 4081.14%. This contributed to the annual value of $2.8 million for FY2024, which is 6665.86% down from last year.
- According to the latest figures from Q3 2025, Alaunos Therapeutics' Liabilities and Shareholders Equity is $3.7 million, which was up 490.14% from $4.7 million recorded in Q2 2025.
- In the past 5 years, Alaunos Therapeutics' Liabilities and Shareholders Equity registered a high of $128.5 million during Q1 2021, and its lowest value of $2.1 million during Q1 2025.
- In the last 5 years, Alaunos Therapeutics' Liabilities and Shareholders Equity had a median value of $27.9 million in 2023 and averaged $45.6 million.
- Per our database at Business Quant, Alaunos Therapeutics' Liabilities and Shareholders Equity plummeted by 8758.79% in 2024 and then surged by 490.14% in 2025.
- Quarter analysis of 5 years shows Alaunos Therapeutics' Liabilities and Shareholders Equity stood at $94.9 million in 2021, then crashed by 31.55% to $64.9 million in 2022, then tumbled by 87.28% to $8.3 million in 2023, then plummeted by 66.66% to $2.8 million in 2024, then surged by 35.17% to $3.7 million in 2025.
- Its Liabilities and Shareholders Equity was $3.7 million in Q3 2025, compared to $4.7 million in Q2 2025 and $2.1 million in Q1 2025.